ClinicalTrials.gov
public full text
Public Domain
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied once daily over 7 days in addition to standard therapy including a beta-blocker. The aim of the study is to assess if a 7 day treatment with BAY1067197 is well tolerated when given on top of standard therapy for heart failure. Furthermore, the study aims to assess if cardiac function improves in the early course of therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker#896747
- Baroreflex Activation Therapy for Heart Failure#1246566
- Baroreflex activation therapy in heart failure - the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) trial rationale and design#226812
- Heart Rate Reduction in Heart Failure#898622
- Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure#835103
Record · ID 1322635
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive